Showing results (271-280 of 301) with videos related to
Sort By:
Pageof 31
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2023
Impact of simulated reduced injected dose on the assessment of amyloid PET scansPeter Young, Fiona Heeman, Jan Axelsson, et al.The New Phytologist|December 25, 2019
Host-specific competitiveness to form nodules in Rhizobium leguminosarum symbiovar viciaeStéphane Boivin, Nassima Ait Lahmidi, David Sherlock, et al.JCI Insight|May 24, 2022
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronavirusesAnna L McNaughton, Robert S Paton, Matthew Edmans, et al.Orphanet Journal of Rare Diseases|October 17, 2021
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1AShahram Attarian, Peter Young, Thomas H Brannagan, et al.Journal of Neurology|June 24, 2015
Mutation screen reveals novel variants and expands the phenotypes associated with DYNC1H1Alleene V Strickland, Maria Schabhüttl, Hans Offenbacher, et al.International Journal of Systematic and Evolutionary Microbiology|May 30, 2019
Minimal standards for the description of new genera and species of rhizobia and agrobacteriaPhilippe M de Lajudie, Mitchell Andrews, Julie Ardley, et al.Neuromuscular Disorders : NMD|February 17, 2019
Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose studyLoren D M Pena, Richard J Barohn, Barry J Byrne, et al.Molecular Genetics and Metabolism|July 31, 2016
Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY StudyAns van der Ploeg, Pierre G Carlier, Robert-Yves Carlier, et al.Neurology|May 26, 2022
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe DiseaseMazen M Dimachkie, Richard J Barohn, Barry Byrne, et al.European Journal of Neurology|November 26, 2025
Tablet-Assisted Speech and Language Therapy for Acute Post-Stroke Aphasia: A Randomized Clinical Trial (LEXI Study)Johannes Wischmann, Leanna Brasch, Julia Franzen, et al.Pageof 31